About HLA class II histocompatibility antigen, DQ alpha 2 chain
HLA class II histocompatibility antigen, DQ alpha 2 chain (HLA-DQA2) is a protein
from Homo sapiens identified by UniProt accession
P01906, 255 residues long.
MolForge cross-references it against 0 known binders and
403 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DQ alpha 2 chain |
|---|
| UniProt accession | P01906 |
|---|
| Gene | HLA-DQA2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 255 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (403)
Diseases linked to this target (Open Targets).
- multiple sclerosis · score 0.31
- Alzheimer disease · score 0.31
- Parkinson disease · score 0.31
- lysosomal storage disease · score 0.31
- neurodegenerative disease · score 0.31
- glioblastoma multiforme · score 0.26
- diabetes mellitus · score 0.25
- complication · score 0.25
- chronic hepatitis B virus infection · score 0.23
- narcolepsy-cataplexy syndrome · score 0.20
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01906-F1 | alphafold | PREDICTED | 88.65 | — |
Amino-acid sequence (255 residues)
MILNKALLLG ALALTAVMSP CGGEDIVADH VASYGVNFYQ SHGPSGQYTH EFDGDEEFYV DLETKETVWQ LPMFSKFISF DPQSALRNMA VGKHTLEFMM RQSNSTAATN EVPEVTVFSK FPVTLGQPNT LICLVDNIFP PVVNITWLSN GHSVTEGVSE TSFLSKSDHS FFKISYLTFL PSADEIYDCK VEHWGLDEPL LKHWEPEIPA PMSELTETLV CALGLSVGLM GIVVGTVFII QGLRSVGASR HQGLL
Explore HLA class II histocompatibility antigen, DQ alpha 2 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets